Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- ART Initiates Clinical Trials of the SoftScan'R' System at the University of California-San Diego as Part of its North American Pivotal Study.
- MONTREAL, CANADA, Mar 29, 2006 CCNMatthews via COMTEX -- The University of California-San Diego participates in the clinical trial of this unique and innovative breast cancer diagnosis technology MONTREAL, CANADA, Mar 29, 2006 CCNMatthews via COMTEX -- The University of California-San Diego participates in...
- Research articles 2006-03-29
- Allstate Workplace Division Sponsors Clinical Trial for Breast Cancer Vaccine
- JACKSONVILLE, Fla. -- Allstate Workplace Division, a subsidiary of The Allstate Corporation, has funded a grant for $220,426 through Gateway for Cancer Research formerly known as Cancer Treatment Research Foundation to support a Phase I Clinical Trial of a vaccine that may fight Stage IV breast cancer.
- Research articles 2007-07-25
- Breast Cancer Center of Excellence Awarded $10 Million Department of Defense Grant; rhIGFBP-3 Selected as a Candidate Agent in Clinical Trials
- Business Editors/Health/Medical Writers
- Research articles 2004-05-13
- Celsion Corporation Completes Phase I Clinical Trial of Its Breast Cancer Treatment System
- Business Editors & Medical Writers
- Research articles 2000-08-01
- ImClone Systems initiates breast cancer clinical trial with lead cancer therapeutic; Phase Ib/IIa study to evaluate anti-tumor activity of C225
- NEW YORK--BUSINESS WIRE--March 5, 1996--ImClone Systems Incorporated (Nasdaq: IMCL) today announced the initiation of an additional Phase Ib/IIa clinical trial for the Company's lead cancer therapeutic, C225, an epidermal growth factor receptor EGFr antagonist. The dose escalation study will evaluate C225 in conjunction with the chemotherapeutic agent Taxol in...
- Research articles 1996-03-05
Additional Resources
- Immunicon Corporation to Conduct Circulating Tumor Cell Testing for Breast Cancer Clinical Trial Conducted by the Southwest Oncology Group
- HUNTINGDON VALLEY, Pa. -- Immunicon Corporation (NASDAQ-GM:IMMC) announced today that a major clinical trial conducted by the Southwest Oncology Group SWOG has opened to enrollment. The trial is a randomized Phase III trial designed to determine whether changing cancer therapy when circulating tumor cells CTCs are elevated at the first...
- Research articles 2006-11-28
- First Patients Enrolled in Three Breast Cancer Studies for Bioenvision's Modrenal®
- NEW YORK -- Bioenvision (Nasdaq:BIVN) today announced that the first patients have been enrolled and commenced treatment in three separate, clinical studies of ModrenalR trilostane. These studies are investigating the efficacy of Modrenal in three distinct settings: (1) a Phase IV trial in advanced, post-menopausal breast cancer, (2) a Phase...
- Research articles 2005-11-17
- Immunicon Corporation Announces Independent Studies to Be Presented at 2007 San Antonio Breast Cancer Symposium That Confirm Utility of the CellSearch™ Circulating Tumor Cell Kit
- Poster Presentations to Address Circulating Tumor Cell CTC Pre-Clinical and Clinical Trial Results in Metastatic Breast Cancer MBC
- Research articles 2007-12-11
- Martin Memorial to Participate in International Clinical Trial for Breast Cancer sponsored by ART
- The Robert and Carol Weissman Cancer Center at Martin Memorial will be one of eight facilities in the U.S. and Canada to test SoftScan, a new diagnostic technology developed by ART Advanced Research Technologies (TSX:ARA) The Robert and Carol Weissman Cancer Center at Martin Memorial is taking part in...
- Research articles 2006-04-24
- Martin Memorial to Participate in International Clinical Trial for Breast Cancer sponsored by ART.
- STUART, FLORIDA, Apr 24, 2006 CCNMatthews via COMTEX -- The Robert and Carol Weissman Cancer Center at Martin Memorial will be one of eight facilities in the U.S. and Canada to test SoftScan, a new diagnostic technology developed by ART Advanced Research Technologies (TSX:ARA) ...
- Research articles 2006-04-24
- Clinical Trial at Arkansas Cancer Research Center Demonstrates Breast Cancer Treatment Using RITA Medical Systems Radiofrequency Ablation Products Reduces Re-Excision Rates by 86%
- FREMONT, Calif. & LITTLE ROCK, Ark. -- Presentation Made October 18th at the 2005 American College of Surgeons 91st Annual Clinical Congress in San Francisco RITA Medical Systems, Inc. (Nasdaq:RITA), a publicly-traded medical device company focused solely on cancer therapies, and the University of Arkansas for Medical Sciences today...
- Research articles 2005-10-19
- Sonus Pharmaceuticals to Present TOCOSOL® Paclitaxel Clinical Data in Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
- SEATTLE -- Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced the scheduled presentation of a poster on TOCOSOLR Paclitaxel at the upcoming San Antonio Breast Cancer Symposium, to be held in San Antonio, Texas from December 8-11. The poster presentation will include efficacy data from an ongoing Phase 2 trial in metastatic...
- Research articles 2005-12-02
- MethylGene Initiates Phase I/II Combination Clinical Trial with its Proprietary HDAC Inhibitor, MGCD0103, and Gemzar'R' in Patients with Pancreatic Cancer
- MethylGene Inc. (TSX: MYG), along with its partner Pharmion Corporation (NASDAQ: PHRM), today announced the initiation of a Phase I/II clinical trial (Trial 006) evaluating its isotype-specific histone deacetylase HDAC inhibitor product candidate, MGCD0103, in combination with Gemzar® (gemcitabine HC1; Eli Lilly and Company) in patients with solid tumors, including...
- Research articles 2006-10-25
- ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
- NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that it has reached agreement with the U.S. Food and Drug Administration FDA under a Special Protocol Assessment SPA for its planned Phase III clinical trial...
- Research articles 2008-04-22
- MethylGene and Pharmion Initiate Phase I Combination Clinical Trial With MGCD0103 and Taxotere(R) in Patients With Solid Tumors
- MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today announced the initiation of a Phase I clinical trial (Trial 011) evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor HDACi product candidate, in combination with Taxotere® (docetaxel; Sanofi Aventis) in patients with solid tumors. Taxotere is an approved chemotherapy agent...
- Research articles 2007-10-10
- Preliminary data shows HDC+BMT combo therapy doesn't affect breast cancer survival rate; results questioned
- The combination of high-dose chemotherapy plus bone marrow transplantation (HDC+BMT) in women with advanced breast cancer does not confer a survival advantage compared with conventional chemotherapy and radiation, according the American Society of Clinical Oncology ASCO. Only 1 in 5 studies conducted over the past 10 years in the...
- Research articles 1999-04-30
- First Patients Enrolled in Phase II and Phase IV Breast Cancer Studies for Bioenvision's Modrenal®
- NEW YORK -- Bioenvision (Nasdaq NM: BIVN) today announced that the first seven patients had been enrolled in a Phase IV clinical study of ModrenalR trilostane in post-menopausal women with advanced breast cancer. The trial has been designed to evaluate the efficacy of ModrenalR in patients who have failed prior...
- Research articles 2005-09-21
- Mentor Capital: Risk Mitigated Call Option on Cancer Immunotherapy
- Mike Havrilla submits:The stock research section of BioMedReports.com has been updated to include my 8-page report for Mentor Capital (MNTR.PK), which is current as of the 8/28/09 publication date. Highlights from the report that make Mentor’s stock a compelling investment for individuals interested in the small/micro-cap biomed space are outlined...
- External links 2009-08-30
- Pfizer Suspends Lung Cancer Study
- Pfizer has stopped entering new patients into the most advanced clinical trial of its experimental lung cancer drug because those who received it were more likely to suffer serious side effects and die. The conclusions are not definitive. Patients enrolled in the study will continue to get the drug, figitumumab....
- News items 2009-10-09
- Sonus Pharmaceuticals Completes Special Protocol Assessment Process with FDA for TOCOSOL® Paclitaxel Phase 3 Clinical Trial in Breast Cancer
- BOTHELL, Wash. -- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) today announced that the U.S. Food and Drug Administration FDA has completed a Special Protocol Assessment SPA for the pivotal Phase 3 trial of the Company's lead cancer product candidate, TOCOSOLR Paclitaxel. Final written communication from the FDA, dated June 30 and received...
- Research articles 2005-07-07
- << Previous
- page 1 of 1
- Next >>
